Cartesian Therapeutics, Inc. (NASDAQ:RNAC) insiders are likely feeling disappointed as the stock took a hit, dropping by 10% following recent purchases. The decline in stock value may have caught insiders off guard, leading to disappointment among those closely involved with the company.